JWJan G. J. van de Winkel

Jan G. J. van de Winkel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan G. J. van de Winkel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Protein 4.1G binds to a unique motif within the FcγRI cytoplasmic tail

    by Jeffrey M. Beekman, Jantine E. Bakema, Cees E. van der Poel, Joke A. van der Linden, Jan G.J. van de Winkel, Jeanette H.W. Leusen


  • Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumour cytotoxicity

    by Lisette Bevaart, Joel Goldstein, Laura Vitale, Christina Russoniello, John Treml, Jun Zhang, Robert F. Graziano, Jeanette H. W. Leusen, Jan G. J. van de Winkel, Tibor Keler

    Summary: Expression of the type I receptor for Fc domain of immunoglobulin (Ig)G (FcγRI or CD64) is restricted to myeloid effector cells, such as monocytes, macrophages and a subset of dendritic cells. Previous work has indicated a role for FcγRI in antibody‐dependent phagocytosis and lysis of tumour cells. We hypothesised that tagging of tumour cells with an anti‐FcγRI single chain Fv (sFv) may facilitate targeting to this receptor on effector cells, thereby initiating tumour cytotoxicity. A vector encoding the sFv for an FcγRI‐specific antibody (H22), linked to the transmembrane domain of platelet‐derived growth factor was constructed. Transfected tumour cells expressed high surface levels of functional H22‐sFv, which greatly enhanced susceptibility for phagocytosis and lysis by monocytes and macrophages. The expression of H22‐sFv evoked the ability of tumour cells to directly activate monocytes, as evidenced by phosphorylation of mitogen‐activated protein kinase and secretion of the inflammatory cytokines interleukin (IL)‐1β, tumour necrosis factor‐α and IL‐6. Moreover, growth of tumour cells in mice expressing H22‐sFv was profoundly delayed (or absent) in transgenic mice expressing human FcγRI. These results demonstrated that tumour cells can be readily modified to activate cell effector mechanisms, a strategy that may be useful for in vivo targeting in patients.


  • Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development

    by Liana Steeghs, Jan Tommassen, Jeanette H.W. Leusen, Jan G.J. van de Winkel, Peter van der Ley

    The use of lipopolysaccharide (LPS) as an adjuvant is limited by its high endotoxic activity. In particular, the fatty-acyl pattern of the lipid A part of LPS has been demonstrated to determine its biological activity. By genetic modification of the lipid A biosynthesis pathway in Neisseria meningitidis, a panel of recombinant strains with specific alterations in the lipid A acylation pattern, as well as a strain completely lacking LPS were isolated. Whereas all variations in the fatty-acyl pattern resulted in reduced endotoxic activity, as measured by TNF-alpha induction in the human macrophage cell line MM6, the adjuvant activity of the modified LPS was, in most cases, barely affected. The in vivo adjuvant properties of N. meningitidis wild-type and mutant LPS was found to correlate with induction of co-stimulatory molecules, in particular CD80 and CD40, and with IL-12 production by LPS-stimulated bone marrow-derived BALB/c dendritic cells in vitro. Our results suggest that the ability of LPS to stimulate pro-inflammatory cytokine induction is not necessarily linked to its adjuvant activity. The availability of this novel set of lipid A variants with improved pharmacological properties will be of great importance for the improvement of future outer membrane vesicle vaccines against N. meningitidis.


    • 1 September 2003
      • Vol. 63  (17) , 5595-600

    CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

    by Heidi H Van Ojik, Lisette Bevaart, Christopher E Dahle, Annie Bakker, Marco J H Jansen, Martine J Van Vugt, Jan G J Van De Winkel, George J Weiner

    Immunostimulatory CpG oligodeoxynucleotides (ODNs) can enhance the therapeutic effect of monoclonal antibodies (mAbs) by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Distinct classes of CpG ODNs have been found recently to stimulate different effector cell populations. We used murine cancer models to explore the role of various effector cell populations in the antitumor activity seen with mAbs combined with CpG ODNs of the A and B classes. In the 38C13 syngeneic murine lymphoma model, both CpG A and CpG B enhanced the efficacy of murine antilymphoma mAb. Depletion of natural killer (NK) cells alone markedly decreased the efficacy of therapy with mAbs plus CpG A. In contrast, depletion of both NK cells and granulocytes was required to decrease the efficacy of mAb plus CpG B. A human (h) Fc gamma receptor I (FcgammaRI)-expressing transgenic (Tg) mouse model was used to explore the role of FcgammaRI in therapy with mAb and CpG ODN. CpG B induced up-regulation of FcgammaRI in hFcgammaRI Tg mice, whereas CpG A did not. In vitro CpG B also enhanced ADCC of HER-2/neu-expressing tumor cells by the FcgammaRI-directed bispecific antibody MDX-H210 using hFcgammaRI-positive effector cells. In a solid tumor model, tumor growth was inhibited in Tg mice treated with a combination of MDX-H210 and CpG B. These data suggest that CpG A enhance ADCC largely by activating NK cells. In contrast, other effector cell populations, including granulocytes, contribute to the antitumor activity of CpG B and mAbs. FcgammaRI plays an important role in this activity.


  • Open Access

    Role of Leukocyte Immunoglobulin G Receptors in Vaccine‐Induced Immunity toStreptococcus pneumoniae

    by Eirikur Saeland, Jeanette H. W. Leusen, Gestur Vidarsson, Wietse Kuis, Elisabeth A. M. Sanders, Ingileif Jonsdottir, Jan G. J. van de Winkel

    Members of the leukocyte immunoglobulin (Ig) G receptor (FcγR) family play a key role in antibody-mediated phagocytosis and can either enhance antigen presentation or down-modulate immune responses. We studied immune responses to a pneumococcal conjugate (pneumococcal polysaccharide serotype 1 [PPS1]-tetanus toxoid) and antibody-mediated protection in mice deficient for individual FcγRs and complement receptor 3 (CR3). FcR γ chain-deficient (FcR γ chain−/−) mice, which lack expression of both FcγRI and III, had significantly lower anti-PPS1 IgG2b and IgG3 responses than did wild-type mice, whereas FcγRII-deficient (FcγRII−/−) mice had significantly higher IgG2a and IgG3 titers. Wild-type and FcγRII−/− mice were protected against infection with pneumococcal serotype 1, whereas immunized FcR γ chain−/− and FcγRIII-deficient mice were not. Immunized CR3-deficient mice were protected against disease, and complement depletion had little effect on protection. These data indicate that activatory leukocyte FcγR, but not FcγRII (a murine homologue of human FcγRIIb), contributes to IgG-mediated protection against pneumococcal disease


  • Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors

    by Nina M. van Sorge, Leonard H. van Den Berg, Karin Geleijns, Jos A. van Strijp, Bart C. Jacobs, Pieter A. van Doorn, John H. J. Wokke, Jan G. J. van de Winkel, Jeanette H. W. Leusen, W‐Ludo van der Pol

    Guillain–Barré syndrome (GBS) is an immune-mediated neuropathy, in which leukocytes and humoral components of the immune system proposedly initiate localized inflammation. An important pathogenic role for anti–GM1 ganglioside antibodies has been suggested. Therefore, we evaluated anti-GM1 IgG antibody-induced leukocyte effector functions such as degranulation and phagocytosis using serum of 24 GBS patients. Serum without anti-GM1 antibodies of 9 GBS patients as well as pooled serum from healthy individuals served as controls. Ten out of 15 (67%) of anti-GM1 IgG positive sera were capable of inducing leukocyte degranulation, and 8 out of 15 (53%) of anti-GM1 IgG positive sera were capable of inducing phagocytosis of GM1-coated beads. In all of these sera anti-GM1 antibody titers were ≥1:800. No leukocyte degranulation or phagocytosis was observed in control sera. Leukocyte activation was completely abrogated in the presence of IgG receptor (FcγR) blocking antibodies, suggesting a crucial role for leukocyte FcγR in GBS pathogenesis. No correlation of antibody titers with the extent of leukocyte activation, or severity of disease was observed. These data document the capacity of anti-GM1 IgG antibodies to activate leukocyte inflammatory functions, and suggest an important role for anti-ganglioside IgG antibodies in the pathogenesis of GBS.